
Disease & Drugs
Clinical Trials
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Clinical Trials
Clinical TrialsCullinan Reports 4 Renal Responses With Velinotamig in Lupus StudyInterim Phase 1b/2a findings presented at ACR Convergence 2026 show that velinotamig achieved reported complete renal response thresholds in four patients within 24 weeks, while eight of nine…Fact-Checked
Clinical TrialsAulos Reports 9.1-Month PFS with Imneskibart in MelanomaAulos Bioscience reports Phase 2 findings for imneskibart combinations in checkpoint inhibitor-refractory melanoma and NSCLC.Fact-Checked
Clinical TrialsObsidian’s Amsoki-cel Shows 67% ORR in ICI-Resistant MelanomaObsidian Therapeutics reported a 67% objective response rate with investigational TIL therapy amsoki-cel in ICI-resistant advanced melanoma.Fact-Checked
Clinical TrialsGilead Reports 75.4% ALP Normalization With Livdelzi in IDEAL TrialGilead’s Phase 3 IDEAL study found that 75.4% of patients receiving Livdelzi (seladelpar) achieved the ALP normalization composite endpoint at Week 52, compared with 16.1% on placebo.Fact-Checked
Fact-Checked
Clinical TrialsBrii Bio Shows Improved HBsAg Loss With BRII-179 Triple TherapyBrii Bio’s Phase 2 ENRICH and ENHANCE studies demonstrate HBsAg loss with BRII-179-based immune-priming regimens in chronic hepatitis B.Fact-Checked
Clinical TrialsIpsen Reports 85.3% ALP Normalization With IQIRVO in PBCIpsen’s IQIRVO (elafibranor) achieved ALP normalization in 85.3% of patients with primary biliary cholangitis at Week 52 in the Phase III ELSPIRE study, compared with 23.3% receiving placebo.…Fact-Checked
Clinical TrialsZai Lab Reports Broad Tumour Responses With Zocilurtatug in epNECZai Lab’s investigational DLL3-targeting ADC zocilurtatug pelitecan achieved a 40% confirmed objective response rate in previously treated extrapulmonary neuroendocrine carcinomas, with a median response duration of 5.6 months.…Fact-Checked
Clinical TrialsCaldera Reports CLD-423 Data, Expands Pipeline Through Qyuns DealCaldera Therapeutics reported updated Phase 1a findings for its IL-23p19 × TL1A bispecific antibody CLD-423, supporting planned Phase 2 studies in inflammatory bowel disease.Fact-Checked
Clinical TrialsAmgen Links Repatha to 20% Lower Heart Attack Rate Than EzetimibeAmgen reported real-world findings showing that Repatha (evolocumab) was associated with a 20% lower rate of fatal or nonfatal myocardial infarction than ezetimibe among 544,103 adults with atherosclerotic…Fact-Checked
Clinical TrialsIksuda Reports 53% Response Rate for IKS03 in B-Cell LymphomaIksuda Therapeutics reported a 53% objective response rate for its investigational CD19-directed ADC IKS03 in a Phase 1 study of heavily pretreated B-cell non-Hodgkin lymphoma.Fact-Checked
Clinical TrialsCitius Reports LYMPHIR Quality-of-Life Improvements in CTCLCitius Oncology reports exploratory quality-of-life findings from LYMPHIR Study 302, highlighting improvements in skin-related well-being, overall quality of life and sustained itch reduction among clinical responders with relapsed…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.